How did VentureWell contribute to your leadership development and your professional trajectory?
Participating in VentureWell’s Aspire Medtech program came at a formative stage in Coredio’s journey. As first-time founders, we had the clinical insight and technical innovation, but we needed structure to communicate our value clearly. VentureWell helped sharpen my leadership mindset—from being focused primarily on building technology to leading a venture with clarity, priorities, and external alignment.
What’s a key learning or takeaway from the VentureWell program you participated in, and how did it impact your journey?
The importance of narrative discipline: being able to express a complex innovation clearly to different audiences—clinicians, investors, regulators, and health systems—without diluting scientific rigor. VentureWell’s mentorship helped us refine our pitch deck, data room structure, and scientific storytelling in a way that resonated with decision-makers. That clarity had a direct impact on our subsequent fundraising discussions, strategic partnerships, and clinical advisory recruitment.
What’s the biggest change or milestone your institution or venture has experienced since participating in VentureWell programming?
Since the program, our company has completed multiple Institutional Review Board (IRB)–approved clinical validation studies, built our digital twin–based non-invasive hemodynamic monitoring platform, and secured foundational partnerships with leading cardiology centers. We raised our pre-seed round, expanded our advisory board with nationally recognized cardiologists and regulatory experts, and advanced toward U.S. Food and Drug Administration (FDA) Breakthrough designation.